Fig. 3From: A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionTime to return to baseline NS3 sequence* in the parent Phase IIb/III studies. *From time of failure; considering the 18 NS3 positions of interest: 36, 41, 43, 54, 55, 80, 107, 122, 132, 138, 155, 156, 158, 168, 169, 170, 174 and 175. EOS end of study, GT genotype, HCV hepatitis C virusBack to article page